Turkey's pharma market isn't as high-profile as the oft-celebrated China or India. But that doesn't mean foreign drugmakers aren't looking for ways to beef up their operations in the country.
Nitto Denko and Dainippon Sumitomo have started a Phase II trial of a transdermal patch delivering Dainippon Sumitomo's antipsychotic Lonasen (blonanserin), which has been launched in Japan and South Korea.
Japanese devicemaker Terumo is proposing a merger with Olympus, following similar moves by Sony and Fujifilm, The Wall Street Journal and Bloomberg are reporting.
Without emerging markets, Japan and consumer heatlhcare, GlaxoSmithKline's second quarter earnings announcement would just be a sea of negative numbers. Thanks to positives in those three areas, overall sales were down just 2%. Europe and U.S. on the other hand, are in a world of hurt.
Japan's Chugai Pharmaceutical is investing more than $150 million over 5 years to investigate antibodies at a new research facility in Singapore.
Since Arena won approval for its Belviq drug, analysts in the U.S. have been weighing in about the drug's prospects. Now, analysts in Japan have added their two cents.
Since Arena Pharmaceuticals won approval for its Belviq drug, analysts in the U.S. have been weighing in about the drug's prospects. Now, analysts in Japan have added their two cents.
With their company, Nipponica, 6 American entrepreneurs are working to bridge the medical technology gap between America and Japan and cash in on Japan's $32 billion device market in the process.
Infraredx found a partner to help boost its presence in Asia and stands to make at least $50 million in the process. The Burlington, MA imaging device maker finalized an agreement with Nipro, a Japanese medical device and pharmaceutical conglomerate, to distribute its TVC imaging system in the country to help diagnose and treat coronary artery disease.
Olympus ($OCPNY) is seriously mulling whether to raise about $628 million to bolster its finances in the wake of a massive accounting scandal. The odds are 50/50 that the Japanese maker of endoscopes and cameras will do this either by forming an alliance with a competitor or selling shares to the public, company president Hiroyuki Sasa confirmed to Bloomberg.